Allspring SMID Cap Growth Fund Q1 2026: Who Moved The Needle

The Allspring SMID Cap Growth Fund underperformed the Russell 2500 Growth Index in the first quarter ended March 31, 2026, but the portfolio commentary highlighted constructive fundamentals for Carpenter Technology and Argan. Carpenter Technology is benefiting from higher Boeing production rates and regulatory approvals, while Argan is seeing pricing power and strong demand across gas-fired and renewable power projects tied to grid modernization. Overall tone is positive on the named holdings, though the fund-level note is only a performance update.

Analysis

The cleaner read-through is that this is less a simple aerospace recovery trade than a capacity-leverage story. CRS has a relatively scarce product set, so incremental OEM production tends to flow through disproportionately to pricing and mix before it shows up in broad industrial datapoints; that makes the setup more durable than a generic cyclical beta trade. The second-order winner is the upstream specialty materials ecosystem: tighter schedules at large defense/aerospace programs usually force buyers to lock in inventory earlier, which can extend order visibility for adjacent suppliers even if end-demand is only modestly improving.

AGX looks like a better risk/reward than the headline suggests because grid-modernization spending creates a multi-year backlog conversion cycle, not just a one-quarter revenue bump. The market often underestimates the option value in scarce EPC capacity: when project starts are constrained, contractors can reprice faster than investors expect, especially on large gas-fired projects where schedule certainty is worth more than lowest-bid economics. The main knock-on effect is negative for smaller EPC peers that lack balance-sheet scale and procurement reach; they may see margin compression as owners prioritize execution quality over headline bid price.

BA is the weak link in the chain rather than a direct beneficiary, because higher production rates help suppliers before they help the OEM's own margin profile. If this production step-up is driven by delivery normalization rather than demand acceleration, supplier wins can coexist with lingering quality, working-capital, or certification risk at the airframer. That creates a useful hedge: you can own the parts-and-materials beneficiaries while remaining skeptical of the OEM until the cadence translates into sustained free-cash-flow inflection.

The consensus may be underestimating how little improvement is needed for CRS and AGX to re-rate if the next 2-3 quarters confirm backlog conversion and margin stability. The bigger risk is timing: if Boeing rates stall or project awards slip, these names can give back quickly because a lot of the optimism is tied to execution, not macro growth. In other words, the opportunity is decent, but the catalyst path is measured in months, not days, and the cleanest trades should be structured around that lag.

Key Decisions for Investors

• Long CRS vs. short BA for a 3-6 month horizon: own the supplier with more direct operating leverage while hedging away OEM execution risk; target a 15-20% relative move if production cadence holds.
• Initiate a tactical long AGX on pullbacks over the next 2-4 weeks; the setup favors backlog-driven earnings compounding over 12 months, with upside if project awards keep pricing disciplined.
• Avoid chasing BA outright until there is evidence that higher build rates are converting to free-cash-flow improvement; if long, use call spreads rather than stock to cap downside from execution noise.
• Pair AGX long against a basket of smaller EPC/engineering peers over 3-6 months to express the view that scarce scale and execution quality will win pricing power as infrastructure spend accelerates.
• If CRS rallies sharply on aerospace optimism, trim into strength and keep exposure via options; the move is likely to be front-loaded while the fundamental confirmation phase still takes a few quarters.